InsidersTradesSigma
Follow the Tactile Systems Technology INC stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Tactile Systems Technology INC has recorded 109 public disclosures. Market capitalisation: €540.3m. The latest transaction was reported on 20 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Burns Kristie. The full history is accessible without an account.
109
Insider Decl.
n/a
Thresholds
€43,751
1 ops.
Buy Volume
€2m
33 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Tactile Systems Technology INC Strong Buy (bullish), based on 4 analysts. Average price target: US$38.25.
51Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 6,556 of 29,064 companies
65.3
score / 100
Value57
Quality73
FCF yld7.7%
Earn yld3.6%
EV/EBITDA13.9x
ROE12%
Gross mgn76%
Net mgn5.8%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 August 2026
Declarations109 total
15,000 shares@ €31,100.9672CommonSEC144:0001628280-26-058210
10,978 shares@ US$29.44460.049% mcap29.8% of flowCommon StockSEC:0001837111-26-000007:0
10,978 shares@ US$29.44460.051% mcap42.4% of flowCommonSEC144:0001959173-26-005855
852 shares0Common StockSEC:0001478345-26-000008:0
7,701 shares@ US$28.941767.0% of flowCommon StockSEC:0001968559-26-000005:0
6,246 shares@ US$28.940833.9% of flowCommon StockSEC:0001857721-26-000007:0
10,993 shares@ US$28.940671.1% of flowCommon StockSEC:0001837111-26-000005:0
3,579 shares0Common StockSEC:0001968559-26-000004:0
3,490 shares0Common StockSEC:0001857721-26-000006:0
19,751 shares0Common StockSEC:0001837111-26-000004:0
23,008 shares0Common StockSEC:0001968559-26-000002:0
6,194 shares0Common StockSEC:0001857721-26-000004:0
48,672 shares0Common StockSEC:0001837111-26-000002:0
5,139 shares@ US$28.8527.9% of flowCommon StockSEC:0001857721-26-000002:0
7,762 shares@ US$12.35674.9% of flowCommon StockSEC:0001415889-25-021513:0
2,921 shares@ US$9.940928.1% of flowCommon StockSEC:0001437749-25-016924:0
3,149 shares@ US$9.83100.0% of flowCommon StockSEC:0001437749-25-016138:0
16,078 shares0Common StockSEC:0001437749-25-015798:0
16,078 shares0Common StockSEC:0001437749-25-015796:0
16,078 shares0Common StockSEC:0001437749-25-015795:0
16,078 shares0Common StockSEC:0001437749-25-015802:0
16,078 shares0Common StockSEC:0001437749-25-015800:0
16,078 shares0Common StockSEC:0001437749-25-015801:0
16,078 shares0Common StockSEC:0001437749-25-015794:0
68,162 shares0Common StockSEC:0001437749-25-007530:0
25 of 109 declarations
关于 Tactile Systems Technology INC
Tactile Systems Technology, Inc. 是一家总部位于美国的医疗技术公司，在美国纳斯达克上市，股票代码为 TCMD。该公司开发和商业化用于未得到充分服务的慢性疾病的家用医疗设备，其战略以报销支持疗法、临床医生转诊和直接患者参与为中心。该公司最初于 1995 年在明尼苏达州注册成立，后来在特拉华州重新注册成立，目前总部位于明尼苏达州明尼阿波利斯。它于 2013 年开始以“Tactile Medical”的名义开展业务。([sec.gov](https://www.sec.gov/Archives/edgar/data/1027838/000155837025001096/tcmd-20241231x10k.htm)) Tactile Medical 的核心业务围绕两个主要治疗特许经营权组织。第一个是用于淋巴水肿和慢性静脉功能不全的气动压缩疗法，通过 Flexitouch Plus、Entre Plus 和 Nimbl 系统进行销售。第二个是气道清除疗法，由 AffloVest 领导，这是一种用于某些慢性呼吸系统疾病的便携式高频胸壁振荡背心。实际上，该公司处于医疗技术、慢性病管理和家庭护理的交汇点。其产品设计用于医院外使用，这在支付方和政策制定者日益青睐低成本、家庭治疗途径的环境中是一个重要的差异化因素。([sec.gov](https://www.sec.gov/Archives/edgar/data/1027838/000155837025001096/tcmd-20241231x10k.htm)) 从竞争角度来看，Tactile Medical 强调临床差异化、专有设备而非商品硬件。Flexitouch Plus 是其先进的可编程平台，专为多个身体区域设计，并通过 Kylee 伴侣应用程序支持蓝牙数据报告。Entre Plus 针对需要更简单泵或尚未获得高级设备报销资格的患者。Nimbl 是下一代平台，于 2024 年获得 FDA 批准并在美国商业上市，并于 2025 年进行更广泛的推广活动。该公司还指出，其网络内或合同支付方覆盖范围覆盖美国超过 275 million 人，这突显了报销准入在其商业模式中的重要性。([sec.gov](https://www.sec.gov/Archives/edgar/data/1027838/000155837025001096/tcmd-20241231x10k.htm)) 从地理上看，该业务绝大多数以美国为中心。收入主要来自在美国向患者销售和租赁，以及向耐用医疗设备供应商销售 AffloVest。该公司对其淋巴水肿产品组合采用直接面向患者和直接面向供应商的模式，而呼吸产品则通过 DME 渠道分销。这创建了一个结合临床教育、保险处理和患者入职的混合上市结构。([sec.gov](https://www.sec.gov/Archives/edgar/data/1027838/000155837025001096/tcmd-20241231x10k.htm)) 近期发展具有建设性。2025 年 2 月，Tactile Medical 扩大了 Nimbl 的商业发布范围，将美国下肢淋巴水肿患者纳入其中。在其 2026 年 2 月全年收益发布中，该公司报告 2025 年收入同比增长 12%，并强调毛利率和盈利能力指标有所改善。它还在 2025 年末宣布了第二次股票回购计划，表明更严格的资本回报纪律。对于投资者而言，TCMD 仍然是一个利基的美国医疗技术故事，受报销趋势、产品采用和新平台执行的影响。([globenewswire.com](https://www.globenewswire.com/news-release/2025/02/04/3020263/0/en/Tactile-Medical-Expands-Launch-of-Nimbl-to-Include-Patients-with-Lower-Extremity-Lymphedema.html))
